Lockhart Catherine M, Smith Travis B, Yang Paul, Naidu Malini, Rettie Allan E, Nath Abhinav, Weleber Richard, Kelly Edward J
Department of Pharmaceutics, University of Washington, Seattle, Washington, USA.
Casey Eye Institute, Oregon Health Sciences University, Portland, Oregon, USA.
Br J Ophthalmol. 2018 Feb;102(2):187-194. doi: 10.1136/bjophthalmol-2016-309696. Epub 2017 Jul 11.
Bietti crystalline dystrophy (BCD) is a rare inherited disorder characterised by fine crystalline deposits in the corneal limbus and retinal posterior pole. In 2004, mutations in the gene were identified as the cause of BCD. Here, we describe the report of a homozygous point mutation in a patient with BCD and provide detailed characterisation of functional and structural changes over 20 years.
At regular intervals, the patient underwent repeat ophthalmic evaluations. DNA was extracted from buccal swabs, amplified by standard PCR and analysed for homology to the CYP4V2 sequence. Homology modelling was conducted using Iterative Threading ASSEmbly Refinement and molecular dynamics simulations using GROningen MAchine for Chemical Simulations.
The proband, a 47-year-old woman of German ancestry was diagnosed with crystalline retinopathy at age 25. Over the next 20 years, visual acuity and function gradually declined with progression of retinal pigment epithelium and choroidal atrophy. When first tested at 39 years of age, the multifocal electroretinogram (ERG) was markedly abnormal, more so for the right eye, whereas the full-field ERG was more symmetrical and lagged other measures of visual function. Gene sequencing showed a single C>T point mutation in exon 9 encoding a R400C amino acid change. Computational modelling suggests the mutation impairs function due to loss of a hydrogen bonding interaction with the propionate side chains of the haeme prosthetic group.
This is the first report of a homozygous R400C mutation in CYP4V2 with protein modelling showing high likelihood of enzyme dysfunction. The comprehensive long-term clinical follow-up provides insight into disease progression and highlights possible anti-inflammatory modulation of disease severity.
比埃蒂结晶状角膜视网膜病变(BCD)是一种罕见的遗传性疾病,其特征是角膜缘和视网膜后极出现细小的结晶沉积物。2004年,该基因的突变被确定为BCD的病因。在此,我们报告一例BCD患者的纯合点突变,并提供20年来功能和结构变化的详细特征描述。
患者定期接受重复眼科评估。从口腔拭子中提取DNA,通过标准PCR扩增,并分析其与CYP4V2序列的同源性。使用迭代穿线装配精修法进行同源建模,并使用格罗宁根化学模拟机进行分子动力学模拟。
先证者是一名47岁具有德国血统的女性,25岁时被诊断为结晶性视网膜病变。在接下来的20年里,随着视网膜色素上皮和脉络膜萎缩的进展,视力和视功能逐渐下降。39岁首次检测时,多焦视网膜电图(ERG)明显异常,右眼更明显,而全视野ERG更对称,且落后于其他视功能指标。基因测序显示外显子9中有一个单一的C>T点突变,编码R400C氨基酸变化。计算建模表明,该突变由于与血红素辅基的丙酸侧链失去氢键相互作用而损害功能。
这是首次报告CYP4V2基因纯合R400C突变,蛋白质建模显示酶功能障碍的可能性很高。全面的长期临床随访提供了对疾病进展的深入了解,并突出了可能对疾病严重程度进行抗炎调节的作用。